香港疫苗接种的成本效果分析及疫苗接种规划决策:一项系统综述
该研究系统综述1990至2015年香港疫苗接种成本效果研究,共纳入9项研究、12组比较,覆盖流感、肺炎球菌病、水痘、b型流感嗜血杆菌、甲型肝炎、宫颈癌和轮状病毒疫苗。10组比较计算了ICER,其中4组干预相对现状可节省成本,另3组ICER远低于常用阈值和WHO支付意愿阈值,提示极具成本效果。
要点
- 香港疫苗接种成本效果模型数量少,仅9项研究符合纳入标准。
- 12组比较中10组计算ICER,4组相对现状可节省成本。
- 除b型流感嗜血杆菌、甲型肝炎和HPV疫苗外,其余评估的疫苗干预均被认为可节省成本或极具成本效果。
核心结论
- 香港针对当地人群的疫苗接种成本效果模型较少。
- 除b型流感嗜血杆菌、甲型肝炎和HPV疫苗接种外,香港所有被评估的疫苗和免疫干预与现状相比均被认为可节省成本或极具成本效果。
研究设计与样本
- 通过Pubmed、Web of Science、Embase和OVID Medline数据库检索1990至2015年发表的香港疫苗接种与政府免疫规划相关成本效果研究,进行系统综述。
- 纳入9项符合标准的研究,报告12组疫苗规划的成本效果比较。
- 使用综合卫生经济评价报告标准清单(CHEERS)评估纳入研究的方法学质量。
- 疫苗接种决策信息来自香港疫苗可预防疾病科学委员会(SCVPD)和卫生署。
主要发现
- 12组比较覆盖流感(n=2)、肺炎球菌病(n=3)、流感加肺炎球菌病(n=1)、水痘(n=2)、b型流感嗜血杆菌(n=1)、甲型肝炎(n=1)、宫颈癌(n=1)和轮状病毒(n=1)疫苗。
- 10组比较(83.3%)计算了疫苗接种策略相对现状的增量成本效果比(ICER),结果以每生命年、每质量调整生命年或每伤残调整生命年的美元成本表示。
- 在10组基础情景比较中,4组评估的干预相对现状可节省成本;其余6组中有3组的ICER估计值远低于常用可接受阈值和WHO支付意愿阈值,提示极具成本效果。
- 基于CHEERS清单,7项研究质量为良好,1项为中等,1项为优秀。
- 常见方法学问题为异质性特征描述和研究参数报告。
关键数值与推荐
- 12组比较中10组(83.3%)以每生命年、每质量调整生命年或每伤残调整生命年的美元成本计算ICER。
- 10组基础情景比较中4组干预相对现状可节省成本。
- 其余6组中有3组的ICER估计值远低于常用可接受阈值和WHO支付意愿阈值。
- CHEERS清单质量评估:7项良好、1项中等、1项优秀。
临床怎么用
- 原文未据此给出推荐。
局限性
- 常见方法学问题为异质性特征描述和研究参数报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe and systematically review the modelling and reporting of cost-effectiveness analysis of vaccination in Hong Kong, and to identify areas for quality enhancement in future cost-effectiveness analyses. METHODS: We conducted a comprehensive and systematic review of cost-effectiveness studies related to vaccination and government immunisation programmes in Hong Kong published from 1990 to 2015, through database search of Pubmed, Web of Science, Embase, and OVID Medline. Methodological quality of selected studies was assessed using Consolidated Health Economic Evaluation Reporting Standards checklist (CHEERS). Decision making of vaccination was obtained from Scientific Committee on Vaccine Preventable Diseases (SCVPD) and Department of Health in Hong Kong. RESULTS: Nine eligible studies reporting twelve comparative cost-effectiveness comparisons of vaccination programme for influenza (n=2), pneumococcal disease (n=3), influenza plus pneumococcal disease (n=1), chickenpox (n=2), Haemophilus influenzae b (n=1), hepatitis A (n=1), cervical cancer (n=1) and rotavirus (n=1) were identified. Ten comparisons (83.3%) calculated the incremental cost-effectiveness ratio (ICER) of a vaccination strategy versus status quo as outcomes in terms of cost in USD per life-years, cost per quality-adjusted life-years, or cost per disability-adjusted life-years. Among those 10 comparisons in base-case scenario, 4 evaluated interventions were cost-saving relative to status quo while the ICER estimates in 3 of the 6 remaining comparisons were far below commonly accepted threshold and WHO willingness-to-pay threshold, suggestive of very cost-effective. Seven studies were of good quality based on the CHEERS checklist; one was of moderate quality; and one was of excellent quality. The common methodological problems were characterisation of heterogeneity and reporting of study parameters. CONCLUSIONS: There was a paucity of cost-effectiveness models evaluating vaccination targeted to the Hong Kong population. All evaluated vaccinations and immunisation interventions in Hong Kong, except for Haemophilus influenzae b, hepatitis A and HPV vaccinations, were considered either cost-saving or very cost-effective when compared to status quo.
引用
- Wong CKH, Liao Q, Guo VYW, et al. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review. Vaccine. 2017. PMID: 28476628. doi:10.1016/j.vaccine.2017.04.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。